Document:

EX-10.1

 Exhibit 10.1 

Citrix Systems, Inc. 

851 West Cypress Creek Road 

Fort Lauderdale, FL 33309 
 July 28,
2015 
 Elliott Associates, L.P. 
 Elliott International, L.P.

 Elliott International Capital Advisors Inc. 
 40 West 57th
Street 
 New York, NY 10019 
 Gentlemen: 

This letter (this “Agreement”) constitutes the agreement between Citrix Systems, Inc., a Delaware corporation
(the “Company”), Elliott Associates, L.P., a Delaware limited partnership (“Elliott Associates”), Elliott International, L.P., a Cayman Islands limited partnership (“Elliott
International”), and Elliott International Capital Advisors Inc., a Delaware corporation (together with Elliott Associates and Elliott International, the “Investors”), with respect to the matters set forth below.
Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in paragraph 12 below.  
 1.
Effective as of the date hereof, (a) Asiff S. Hirji shall resign from the Board of Directors of the Company (the “Board”), and (b) the Board shall take such actions as are necessary to appoint Jesse Cohn as a new
member of the Board to fill the vacancy so created (the “Investor Designee”). The Nominating and Corporate Governance Committee of the Board, together with the Investors, will conduct a search process to promptly identify an
additional director mutually agreeable to the Company and the Investors (the “New Independent Director” and together with the Investor Designee, the “New Directors”) to join the Board, and promptly
following identification of such New Independent Director and completion of the Company’s review process, (i) one (1) additional director mutually agreeable to the Company and the Investors shall resign from the Board, and
(ii) the Board shall take such actions as are necessary to appoint the New Independent Director to fill the vacancy so created. The New Independent Director shall qualify as Independent and satisfy the Board membership criteria set forth in the
Company’s Corporate Governance Guidelines. Notwithstanding anything to the contrary contained in this Agreement, if (i) the Investors’ and their controlling or controlled Affiliates’ aggregate beneficial ownership decreases to
less than 3.0% of the Company’s outstanding common stock as a result of dispositions by the Investors and (ii) the Investor Designee has joined the Board, then the Board may in its sole discretion request that the Investor Designee resign
from the Board and any committees thereof, in which case the Investor Designee shall promptly deliver his written resignation to the Board (which shall provide for his immediate resignation) and the obligations of each of the parties hereunder shall
terminate.  

 2. The Company shall include the New Directors on its slate for election as directors of
the Company at its 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”). If the New Independent Director resigns, refuses, or is unable to serve as a director at any time prior to the first anniversary of the date
of this Agreement, the Company and the Investors shall mutually agree on a replacement who is Independent and satisfies the Board membership criteria set forth in the Company’s Corporate Governance Guidelines. Such replacement for the New
Independent Director shall be appointed to the Board to serve the unexpired term of the departed New Independent Director, and shall be considered a New Director for all purposes of this Agreement. If the Investor Designee is unable to serve or
fulfill his duties as a director because of his death or disability prior to the first anniversary of the date of this Agreement, the Investors shall select a replacement who is reasonably acceptable to the Company. Such replacement for the Investor
Designee shall be appointed to the Board to serve the unexpired term of the departed Investor Designee, and shall be considered the Investor Designee and a New Director for all purposes of this Agreement. Any other vacancies on the Board or any
committee thereof created prior to the Expiration Date shall be filled by the Board upon the recommendation of the Nominating and Corporate Governance Committee. The size of the Board shall not exceed ten (10) directors prior to the first
anniversary of the date of this Agreement, except with the prior written consent of the Investors. 
 3. As a condition to a New
Director’s appointment to the Board and any subsequent nomination for election as a director at the Company’s Annual Meeting of Stockholders, the New Director will provide any information the Company reasonably requires, including
information required to be disclosed in a proxy statement or other filing under applicable law, stock exchange rules or listing standards, information in connection with assessing eligibility, independence and other criteria applicable to directors
or satisfying compliance and legal obligations, and will consent to appropriate background checks, to the extent, in each case, consistent with the information and background checks required by the Company in accordance with past practice with
respect to other members of the Board. If, following the completion of the Company’s initial background review process, the Board learns that the Investor Designee has committed, been indicted or charged with, or made a plea of nolo
contendre to a felony or a misdemeanor involving moral turpitude, deceit, dishonesty or fraud, then the Board may request that the Investor Designee submit his resignation and, in such case, the Investors will cause the Investor Designee to resign
from the Board and may select a replacement designee reasonably acceptable to the Board. 
 4. In connection with the 2016 Annual Meeting
(and any adjournments or postponements thereof), the Company will recommend that the Company’s stockholders vote in favor of the election of each of the Company’s nominees (including the New Directors), solicit proxies for each of the
Company’s nominees, and cause all Company common stock represented by proxies granted to it (or any of its officers, directors or representatives) to be voted in favor of each of the Company’s nominees. In connection with the 2016 Annual
Meeting (and any adjournments or postponements thereof), so long as both New Directors have been nominated by the Board for re-election as a director, and at each subsequent Annual Meeting of Stockholders of the Company (and any adjournments or
postponements thereof) at which the Investor Designee has been nominated by the Board for re-election as a director, the Investors will cause to be present for quorum purposes and vote or cause to be voted all Company common stock beneficially owned
by them or their controlling or controlled Affiliates and which they or such 

  
 -2- 

 
controlling or controlled Affiliates are entitled to vote on the record date for the 2016 Annual Meeting or such subsequent Annual Meeting of Stockholders in favor of (A) the election of
directors nominated by the Board and (B) otherwise in accordance with the Board’s recommendation on any non-Extraordinary Transaction related proposals. 

5. The parties hereto acknowledge that each of the New Directors, upon election to the Board, will serve as a member of the Board and
will be governed by the same protections and obligations regarding confidentiality, conflicts of interest, related party transactions, fiduciary duties, codes of conduct, trading and disclosure policies, director resignation policy, and other
governance guidelines and policies of the Company (including, but not limited to, the policies with respect to management being responsible for managing communications with external constituencies) as other directors (collectively,
“Company Policies”), and shall be required to preserve the confidentiality of Company business and information, including discussions or matters considered in meetings of the Board or Board committees, and shall have the same
rights and benefits, including with respect to insurance, indemnification, compensation and fees, as are applicable to all independent directors of the Company. The Company represents and warrants that: (i) all Company Policies currently in
effect are publicly available on the Company’s website or described in its proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2015 or have otherwise been provided to the
Investors, and such Company Policies will not be amended prior to the appointment of the Investor Designee and (ii) during the Restricted Period, any changes to the Company Policies, or new Company Policies, will be adopted in good faith and
not for the purpose of undermining or conflicting with the arrangements contemplated hereby. 
 6. The Company will take all
action necessary to form a committee of the Board as promptly as practicable after the date hereof to conduct a full operating review of the business (the “Operations Committee”). The Operations Committee will evaluate, among
other things, the Company’s operating margins, profitability and capital structure with a mandate to recommend a plan to improve margins, profitability and capital structure (the “Operating Review”). The Operations
Committee will be empowered to hire advisors to assist in its Operating Review. The Operations Committee shall be comprised of four (4) members, consisting of Robert M. Calderoni, Robert D. Daleo, and the New Directors. The Chairman of the
Operations Committee shall be Mr. Calderoni.  
 7. The Company will take all action necessary to form a committee of the
Board as promptly as practicable after the date hereof to conduct the search for a new Chief Executive Officer (the “Search Committee”). The Search Committee will be empowered to identify, review and recommend a new Chief
Executive Officer to the Board. The Search Committee shall be comprised of four (4) members, consisting of Robert M. Calderoni, Godfrey R. Sullivan, and the New Directors. The Chairman of the Search Committee shall be Mr. Calderoni. 

 8. Promptly, and in any event within one business day, following the execution and delivery of this Agreement, the Company
shall substantially concurrently issue three press releases in the forms attached as Exhibit A (the “Company Press Releases”) and no party shall make any statement inconsistent with the Company Press Releases in connection
with the announcement of this Agreement. None of the Investors or their Affiliates shall issue a press release in connection with this Agreement or the actions contemplated hereby. Additionally, 

  
 -3- 

 
promptly following the execution and delivery of this Agreement, the Company will file a Current Report on Form 8-K, which will report the entry into this Agreement. The Investors shall
promptly, but in no case prior to the date of the filing or other public release by the Company of the Company Press Releases, prepare and file an amendment to the Schedule 13D with respect to the Company originally filed by the Investors with the
SEC on June 11, 2015 (the “Schedule 13D”) reporting the entry into this Agreement and amending applicable items to conform to its obligations hereunder. The amendment and the Form 8-K shall each be consistent with the
Company Press Releases and the terms of this Agreement, and shall be in form and substance reasonably acceptable to the Company and the Investors. 

9. From the date of this Agreement until the Expiration Date or until such earlier time as the restrictions in this paragraph 9
terminate as provided herein (such period, the “Restricted Period”), the Investors will not, and will cause their respective Affiliates and their respective principals, directors, general partners, officers, employees, and
agents and representatives acting on their behalf (collectively, the “Restricted Persons”) not to, directly or indirectly, absent prior express written invitation or authorization by the Board: 

(a) engage in any “solicitation” (as such term is used in the proxy rules of the SEC) of proxies or consents with respect to the
election or removal of directors or any other matter or proposal or become a “participant” (as such term is used in the proxy rules of the SEC) in any such solicitation of proxies or consents; 

(b) knowingly encourage or advise any other Person or knowingly assist any Person in so encouraging or advising any Person with respect to the
giving or withholding of any proxy, consent or other authority to vote or in conducting any type of referendum (other than such encouragement or advice that is consistent with Company management’s recommendation in connection with such matter);

 (c) form, join or act in concert with any “group” as defined pursuant to Section 13(d) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), with respect to any Voting Securities, other than solely with other Affiliates of the Investors with respect to Voting Securities now or hereafter owned by them; 

(d) acquire, or offer, seek or agree to acquire, by purchase or otherwise, or direct any third party in the acquisition of, any Voting
Securities or assets of the Company, or rights or options to acquire any Voting Securities or assets of the Company, or engage in any swap or hedging transactions or other derivative agreements of any nature with respect to Voting Securities, in
each case if such acquisition or transaction would result in the Investors having beneficial ownership (voting power or economic exposure) of more than 9.9% of the Company’s outstanding common stock; 

(e) sell, offer or agree to sell, all or substantially all, directly or indirectly, through swap or hedging transactions or otherwise, voting
rights decoupled from the underlying common stock of the Company held by the Investors to any Third Party; 
 (f) make or in any way
participate, directly or indirectly, in any tender offer, exchange offer, merger, consolidation, acquisition, business combination, recapitalization, 

  
 -4- 

 
restructuring, liquidation, dissolution or extraordinary transaction involving the Company or any of its subsidiaries or its or their securities or assets (each, an “Extraordinary
Transaction”) (it being understood that the foregoing shall not restrict the Investors from tendering shares, receiving payment for shares or otherwise participating in any such transaction on the same basis as other stockholders of the
Company, or from participating in any such transaction that has been approved by the Board); or make, directly or indirectly, any proposal, either alone or in concert with others, to the Company or the Board that would reasonably be expected to
require a public announcement regarding any of the types of matters set forth above in this paragraph; 
 (g) enter into a voting trust,
arrangement or agreement or subject any Voting Securities to any voting trust, arrangement or agreement, in each case other than solely with other Affiliates of the Investors, with respect to Voting Securities now or hereafter owned by them and
other than granting proxies in solicitations approved by the Board; 
 (h) (i) seek, alone or in concert with others, election or
appointment to, or representation on, the Board or nominate or propose the nomination of, or recommend the nomination of, any candidate to the Board, except as set forth herein, (ii) seek, alone or in concert with others, the removal of any
member of the Board or (iii) conduct a referendum of stockholders; 
 (i) make or be the proponent of any stockholder proposal
(pursuant to Rule 14a-8 under the Exchange Act or otherwise); 
 (j) make any request for stock list materials or other books and records of
the Company under Section 220 of the Delaware General Corporation Law or other statutory or regulatory provisions providing for shareholder access to books and records; 

(k) except as set forth herein, make any public proposal with respect to (i) any change in the number or term of directors or the filling
of any vacancies on the Board, (ii) any material change in the capitalization or dividend policy of the Company, (iii) any other material change in the Company’s management, business or corporate structure, (iv) any waiver,
amendment or modification to the Company’s Certificate of Incorporation or Bylaws, or other actions which may impede the acquisition of control of the Company by any person, (v) causing a class of securities of the Company to be delisted
from, or to cease to be authorized to be quoted on, any securities exchange or (vi) causing a class of equity securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act;

 (l) institute, solicit, assist or join any litigation, arbitration or other proceeding against or involving the Company or any of its
current or former directors or officers (including derivative actions) in order to effect or take any of the actions expressly prohibited by this paragraph 9; provided, however, that for the avoidance of doubt the foregoing shall not prevent any
Restricted Person from (A) bringing litigation to enforce the provisions of this Agreement, (B) making counterclaims with respect to any proceeding initiated by, or on behalf of, the Company against a Restricted Person, (C) bringing
bona fide commercial disputes that do not relate to the subject matter of this Agreement or the topics covered in the correspondence between the Company and the Restricted Persons prior to the date hereof, or (D) exercising

  
 -5- 

 
statutory appraisal rights; provided, further, that the foregoing shall also not prevent the Restricted Persons from responding to or complying with a validly issued legal process; 

(m) enter into any negotiations, agreements or understandings with any Third Party to take any action that the Investors are prohibited from
taking pursuant to this paragraph 9; or 
 (n) make any request or submit any proposal to amend or waive the terms of this Agreement, in
each case which would reasonably be expected to result in a public announcement of such request or proposal; 
 provided, that the restrictions in this
paragraph 9 shall terminate automatically upon the earliest of (i) as a non-exclusive remedy for any such breach, upon five (5) business days’ prior written notice by the Investors following a material breach of this Agreement by the
Company (including, without limitation, a failure to appoint the New Directors and otherwise constitute the Board in accordance with paragraph 1, a failure to appoint the New Directors to the applicable committees of the Board in accordance with
paragraphs 6 and 7, or a failure to issue the Company Press Releases in accordance with paragraph 8) if such breach has not been cured within such notice period, provided that the Investors are not in material breach of this Agreement at the time
such notice is given, (ii) the announcement by the Company of a definitive agreement with respect to any Extraordinary Transaction that would result in the acquisition by any person or group of more than 50% of the Voting Securities,
(iii) the commencement of any tender or exchange offer (by a person other than the Investors or their Affiliates) which, if consummated, would constitute an Extraordinary Transaction that would result in the acquisition by any person or group
of more than 50% of the Voting Securities, where the Company files a Schedule 14D-9 (or any amendment thereto), other than a “stop, look and listen” communication by the Company pursuant to Rule 14d-9(f) promulgated under the Exchange
Act, that does not recommend that the Company’s stockholders reject such tender or exchange offer, (iv) such time as the Company issues a preliminary proxy statement, definitive proxy statement or other proxy materials in connection with
the 2016 Annual Meeting that are inconsistent with the terms of this Agreement or (v) the adoption by the Board of any amendment to the Certificate of Incorporation or Bylaws of the Company that would reasonably be expected to substantially
impair the ability of a stockholder to submit nominations for election to the Board or stockholder proposals in connection with any future Company Annual Meeting of Stockholders. Notwithstanding anything to the contrary in this Agreement, nothing in
this paragraph 9 shall prohibit or restrict the Investor Designee from exercising his rights and fiduciary duties as a director of the Company or restrict his discussions solely among other members of the Board and/or management, advisors,
representatives or agents of the Company. 
 10. During the Restricted Period, the Company, the Investors and the Investor Designee shall
each refrain from making, and shall cause their respective Affiliates and its and their respective principals, directors, members, general partners, officers and employees not to make or cause to be made any statement or announcement including in
any document or report filed with or furnished to the SEC or through the press, media, analysts or other persons, that constitutes an ad hominem attack on, or otherwise disparages, defames, slanders, impugns or is reasonably likely to damage the
reputation of, (a) in the case of statements or announcements by any of the Investors: the Company or any of its Affiliates, subsidiaries or advisors, or any of its 

  
 -6- 

 
or their respective current or former officers, directors or employees (including, without limitation, any statements or announcements regarding the Company’s strategy, operations,
performance, products or services), and (b) in the case of statements or announcements by the Company: the Investors and the Investors’ advisors, their respective employees or any person who has served as an employee of the Investors and
the Investors’ advisors. The foregoing shall not restrict the ability of any person to comply with any subpoena or other legal process or respond to a request for information from any governmental authority with jurisdiction over the party from
whom information is sought. 
 11. The Company hereby agrees that the Investor Designee may provide confidential information of the Company
to the Investors and their Affiliates subject to, and solely in accordance with the terms of, a confidentiality agreement in the form attached hereto as Exhibit B (which the Investors agree to execute and deliver to the Company simultaneously with
the Investors’ execution and delivery of this Agreement). The Investors and the Investor Designee hereby acknowledge that they and their Affiliates are aware that United States securities laws may restrict any person who has material,
non-public information about a company from purchasing or selling any securities of such company while in possession of such information. Accordingly, the Investors shall, and shall cause their Affiliates to, purchase and sell securities of the
Company only in compliance with the Company’s insider trading policy, a copy of which has been provided to the Investors. 
 12.
As used in this Agreement, the term (a) “Affiliate” shall have the meaning set forth in Rule 12b-2 promulgated under the Exchange Act and shall include Persons who become Affiliates of any Person subsequent to the date
of this Agreement; (b) “beneficially own”, “beneficially owned” and “beneficial ownership” shall have the meaning set forth in Rules 13d-3 and 13d-5(b)(l) promulgated under the Exchange Act and shall include any other economic exposure to Company common stock, including through any swap or other derivative transaction, that gives a Person the economic
equivalent of ownership of Company common stock, including, without limitation, the notional number of shares subject to derivative agreements in the form of cash-settled swaps; (c) “business day” shall mean any day
other than a Saturday, Sunday or a day on which the Federal Reserve Bank of New York is closed; (d) “Expiration Date” means the first anniversary of the date of this Agreement; provided that, if the Investor Designee
remains a director of the Company as of such anniversary date, then the Expiration Date shall be automatically extended until the earlier of (i) the date that the Board fails to re-nominate the Investor Designee as a director of the Company in
connection with an Annual Meeting of Stockholders or (ii) the date that the Investor Designee resigns as a director of the Company (for the avoidance of doubt, it is understood and agreed that the Board shall have no obligation to re-nominate
the Investor Designee as a director of the Company following the 2016 Annual Meeting); (e) “Independent” means that a Person (x) (i) shall not be an employee, director, general partner, manager or other agent
of an Investor or of any Affiliate of an Investor, (ii) shall not be a limited partner, member or other investor in any Investor or any Affiliate of an Investor and (iii) shall not have, and shall not have had, any agreement, arrangement
or understanding, written or oral, with any Investor or any Affiliate of an Investor regarding such Person’s service on the Board, and (y) shall be an independent director of the Company under the Company’s independence guidelines,
applicable law and the rules and regulations of the SEC and Nasdaq Stock Market; (f) “Person” shall be interpreted broadly to include, among others, any individual, general or limited partnership, corporation, limited

  
 -7- 

 
liability or unlimited liability company, joint venture, estate, trust, group, association or other entity of any kind or structure; (g) “Third Party” means any
Person that is not a party to this Agreement or an Affiliate thereof, a member of the Board, a director or officer of the Company, or legal counsel to any party to this Agreement; and (h) “Voting Securities” shall mean
the shares of common stock of the Company and any other securities of the Company entitled to vote in the election of directors, or securities convertible into, or exercisable or exchangeable for, such shares or other securities, whether or not
subject to the passage of time or other contingencies. 
 13. Each of the Investors, severally and not jointly, represents and
warrants that (a) this Agreement has been duly authorized, executed and delivered by it and is a valid and binding obligation of such Investor, enforceable against it in accordance with its terms; (b) neither it nor any of its Affiliates
has or will during the Restricted Period have, any agreement, arrangement or understanding, written or oral, with the New Independent Director or other member of the Board (other than the Investor Designee) pursuant to which such individual has been
or will be compensated for his or her service as a director on, or nominee for election to, the Board; and (c) as of the date of this Agreement, (i) the Investors, together with all of their respective Affiliates, collectively beneficially
own, an aggregate of 11,989,100 shares of Voting Securities and (ii) except as previously disclosed in writing to the Company prior to the execution of this Agreement, none of the Investors nor any of their respective Affiliates, is a party to
any swap or hedging transactions or other derivative agreements of any nature with respect to the Voting Securities. 
 14. The Company
represents and warrants that (a) this Agreement has been duly authorized, executed and delivered by it and is a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms; (b) does not require
the approval of the stockholders of the Company; and (c) does not and will not violate any law, any order of any court or other agency of government, the Company’s Certificate of Incorporation or Bylaws, each as amended from time to time,
or any provision of any agreement or other instrument to which the Company or any of its properties or assets is bound, or conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default under any such
agreement or other instrument, or result in the creation or imposition of, or give rise to, any material lien, charge, restriction, claim, encumbrance or adverse penalty of any nature whatsoever pursuant to any such indenture, agreement or other
instrument. 
 15. The Company and each of the Investors each acknowledge and agree that money damages would not be a sufficient remedy for
any breach (or threatened breach) of this Agreement by it and that, in the event of any breach or threatened breach hereof, (a) the non-breaching party will be entitled to seek injunctive and other equitable relief, without proof of actual
damages; (b) the breaching party will not plead in defense thereto that there would be an adequate remedy at law; and (c) the breaching party agrees to waive any applicable right or requirement that a bond be posted by the non-breaching
party. Such remedies will not be the exclusive remedies for a breach of this Agreement, but will be in addition to all other remedies available at law or in equity. 

16. This Agreement (including its exhibits) constitutes the only agreement between the Investors and the Company with respect to the subject
matter hereof and supersedes all prior 

  
 -8- 

 
agreements, understandings, negotiations and discussions, whether oral or written. This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and
permitted assigns. No party may assign or otherwise transfer either this Agreement or any of its rights, interests, or obligations hereunder without the prior written approval of the other party. Any purported transfer requiring consent without such
consent shall be void. No amendment, modification, supplement or waiver of any provision of this Agreement shall be effective unless it is in writing and signed by the party affected thereby, and then only in the specific instance and for the
specific purpose stated therein. Any waiver by any party of a breach of any provision of this Agreement shall not operate as or be construed to be a waiver of any other breach of such provision or of any breach of any other provision of this
Agreement. The failure of a party to insist upon strict adherence to any term of this Agreement on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter to insist upon strict adherence to that term or
any other term of this Agreement. 
 17. If any provision of this Agreement is held invalid or unenforceable by any court of competent
jurisdiction, the other provisions of this Agreement shall remain in full force and effect. Any provision of this Agreement held invalid or unenforceable only in part or degree shall remain in full force and effect to the extent not held invalid or
unenforceable. The parties further agree to replace such invalid or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the purposes of such invalid or unenforceable provision.

 18. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. Each of the Investors and the
Company (a) irrevocably and unconditionally consents to the personal jurisdiction and venue of the federal or state courts located in Wilmington, Delaware; (b) agrees that it shall not attempt to deny or defeat such personal jurisdiction
by motion or other request for leave from any such court; (c) agrees that it shall not bring any action relating to this Agreement or otherwise in any court other than such courts; and (d) waives any claim of improper venue or any claim
that those courts are an inconvenient forum. The parties agree that mailing of process or other papers in connection with any such action or proceeding in the manner provided in paragraph 20 or in such other manner as may be permitted by applicable
law, shall be valid and sufficient service thereof. Each of the parties, after consulting or having had the opportunity to consult with counsel, knowingly, voluntarily and intentionally waives any right that such party may have to a trial by jury in
any litigation based upon or arising out of this Agreement or any related instrument or agreement, or any of the transactions contemplated thereby, or any course of conduct, dealing, statements (whether oral or written), or actions of any of them.
No party shall seek to consolidate, by counterclaim or otherwise, any action in which a jury trial has been waived with any other action in which a jury trial cannot be or has not been waived. 

19. This Agreement is solely for the benefit of the parties and is not enforceable by any other Person. 

20. All notices, consents, requests, instructions, approvals and other communications provided for herein, and all legal process in regard
hereto, will be in writing and will be deemed validly given, made or served when delivered in person, by electronic mail, by overnight courier 

  
 -9- 

 
or two business days after being sent by registered or certified mail (postage prepaid, return receipt requested) as follows: 

If to the Company to: 
 Citrix
Systems, Inc. 
 851 West Cypress Creek Road 

Fort Lauderdale, FL 33309 
 Attn:
Antonio G. Gomes 
 email: tony.gomes@citrix.com 

with a copy (which shall not constitute notice) to: 

Goodwin Procter LLP 
 53 State
Street 
 Boston, MA 02109-2802 

			
	Attn:	  	Stuart M. Cable
		  	Lisa R. Haddad
	Email:	  	scable@goodwinprocter.com
		  	lhaddad@goodwinprocter.com

 If to the Investors: 

Elliott Associates, L.P. 

Elliott International, L.P. 

Elliott International Capital Advisors Inc. 

40 West 57th Street 
 New York, NY
10019 

			
	Attn:	  	Jesse Cohn
	email:	  	jcohn@elliottmgmt.com

 with a copy (which shall not constitute notice) to: 

Paul, Weiss, Rifkind, Wharton & Garrison LLP 

1285 Avenue of the Americas 
 New
York, NY 10019 

			
	Attn:	  	Robert B. Schumer
		  	Steven J. Williams
	email:	  	rschumer@paulweiss.com
		  	swilliams@paulweiss.com

 At any time, any party may, by notice given in accordance with this paragraph to the other party, provide updated information
for notices hereunder. 
 21. All attorneys’ fees, costs and expenses incurred in connection with this Agreement and all matters
related hereto will be paid by the party incurring such fees, costs or expenses. 

  
 -10- 

 22. Each of the parties acknowledges that it has been represented by counsel of its choice
throughout all negotiations that have preceded the execution of this Agreement, and that it has executed this Agreement with the advice of such counsel. Each party and its counsel cooperated and participated in the drafting and preparation of this
Agreement, and any and all drafts relating thereto exchanged among the parties shall be deemed the work product of all of the parties and may not be construed against any party by reason of its drafting or preparation. Accordingly, any rule of law
or any legal decision that would require interpretation of any ambiguities in this Agreement against any party that drafted or prepared it is of no application and is hereby expressly waived by each of the parties, and any controversy over
interpretations of this Agreement shall be decided without regard to events of drafting or preparation. 
 23. This Agreement may be
executed by the parties in separate counterparts (including by fax, jpeg, .gif, .bmp and .pdf), each of which when so executed shall be an original, but all such counterparts shall together constitute one and the same instrument. 

[Signature page follows] 

  
 -11- 

 If the terms of this Agreement are in accordance with your understanding, please sign below,
whereupon this Agreement shall constitute a binding agreement among us. 
  

			
	Very truly yours,
	
	CITRIX SYSTEMS, INC.
		
	By:	 	 /s/ Antonio G. Gomes

	Name:	 	Antonio G. Gomes
	Title:	 	Senior Vice President, General Counsel

  

					
	Accepted and agreed to as of the date first written above:
	
	ELLIOTT ASSOCIATES, L.P.
		
	By:	 	Elliott Capital Advisors, L.P.,
		 	its General Partner
		
	By:	 	Braxton Associates, Inc.,
		 	its General Partner
		
	By:	 	 /s/ Elliot Greenberg

		 	Name:	 	Elliot Greenberg
		 	Title:	 	Vice President
	
	ELLIOTT INTERNATIONAL, L.P.
		
	By:	 	Elliott International Capital Advisors Inc.,
		 	as Attorney-in-Fact
		
	By:	 	 /s/ Elliot Greenberg

		 	Name:	 	Elliot Greenberg
		 	Title:	 	Vice President
	
	ELLIOTT INTERNATIONAL CAPITAL ADVISORS INC.
		
	By:	 	 /s/ Elliot Greenberg

		 	Name:	 	Elliot Greenberg
		 	Title:	 	Vice President

 [Signature Page to Letter Agreement] 

 Exhibit A 

Company Press Releases 

  
 -13- 

 Exhibit B 

Confidentiality Agreement 

  
 -14- 

 PERSONAL AND CONFIDENTIAL 

July 28, 2015 
 Elliott Asssociates, L.P. 

Elliott International, L.P. 
 Elliott International Capital
Advisors Inc. 
 40 West 57th Street 

New York, NY 10019 
 Ladies and Gentlemen: 

This letter agreement shall become effective upon the appointment of the Investor Designee to the Board of Directors (the “Board”) of
Citrix Systems, Inc. (the “Company”) pursuant to the other letter agreement, dated as of the date hereof, between the Company and you (the “Cooperation Agreement”). Capitalized terms used but not
otherwise defined herein shall have the meanings given to such terms in the Cooperation Agreement. Subject to the terms of, and in accordance with, this letter agreement, you and, subject to the restrictions in paragraph 1, your Representatives and
Affiliates, may receive certain information about the Company and its subsidiaries, divisions and Affiliates from the Investor Designee that is confidential and proprietary and the disclosure of which could harm the Company and its subsidiaries. You
understand and agree that disclosure of any such information by the Investor Designee shall be subject in all cases to his fiduciary duties to the Company and its stockholders and the Company Policies. Without limiting the generality of the
foregoing, it is understood and agreed that the Investor Designee shall not disclose to you or your Representatives or Affiliates (i) any information regarding the deliberations of the Board or its committees as a whole or of individual members
of the Board or its committees or members of the Company’s management (which the parties agree shall not include factual information regarding the Company and its subsidiaries, divisions and Affiliates), (ii) any confidential or
proprietary information of any third party in the possession of the Company and its subsidiaries that either (x) is identified as such to the Investor Designee by or on behalf of the Company or (y) as to which it is reasonably apparent
that the Company or any of its subsidiaries is obligated by a contractual, legal or fiduciary obligation prohibiting disclosure, (iii) any legal advice provided by external or internal counsel to the Company or any of its subsidiaries in
connection with a pending or threatened claim, action or proceeding, or (iv) any other information that may constitute waiver of the Company’s or any of its subsidiaries’ attorney-client privilege or attorney work-product privilege
(both with respect to internal or external legal counsel) that is identified as such to the Investor Designee by or on behalf of the Company. 
 As a
condition of your being furnished such information, you agree to treat any information, whether written or oral, concerning the Company or any of its subsidiaries, divisions or Affiliates 

 
that is furnished to you by or on behalf of the Investor Designee (herein collectively referred to as the “Confidential Information”) in accordance with the provisions of
this letter agreement and to take or abstain from taking certain other actions herein set forth. The term “Confidential Information” includes, without limitation, all notes, analyses, data or other documents furnished to you or your
Affiliates or Representatives or prepared by you or your Affiliates or Representatives to the extent such materials reflect or are based upon, in whole or in part, the Confidential Information. The term “Confidential Information” does not
include information that (a) is or becomes available to you or the Investor Designee on a nonconfidential basis from a source other than the Company or its Affiliates or representatives; provided that such source is not known by you or the
Investor Designee to be bound by a confidentiality agreement with, or other contractual, legal or fiduciary obligation to, the Company that prohibits such disclosure, (b) is or becomes generally available to the public other than as a result of
a disclosure by you or your Representatives or Affiliates in violation of this letter agreement, or (c) has been or is independently developed by you or your Representatives or Affiliates without the use of the Confidential Information or in
violation of the terms of this letter agreement. For purposes of this letter agreement, the term “Representatives” shall include your and your Affiliates’ directors, officers, employees and attorneys. 

 

	 	1.	You hereby agree that the Confidential Information will be kept confidential and used solely for the purpose of monitoring and evaluating your investment in the Company; provided, however, that the Confidential
Information may be disclosed (i) to your Affiliates and any of your Representatives who need to know such information for the sole purpose of advising you on your investment in the Company, (ii) in accordance with paragraph 3 of this
letter agreement, or (iii) as the Company may otherwise consent in writing. All such Affiliates and Representatives shall (A) be informed by you of the confidential nature of the Confidential Information, (B) agree to keep the
Confidential Information strictly confidential, and (C) be advised of the terms of this letter agreement. You agree to be responsible for any breaches of any of the provisions of this letter agreement by any of your Affiliates or
Representatives as if they were party hereto (it being understood that such responsibility shall be in addition to and not by way of limitation of any right or remedy the Company may have against your Affiliates and Representatives with respect to
such breach). 

  

	 	2.	You hereby acknowledge that you, your Affiliates and your Representatives are aware that the Confidential Information may contain material, non-public information about the Company, and that the U.S. securities laws
restrict any person who has material, non-public information about a company from purchasing or selling any securities of such company while in possession of such information, and further acknowledge your obligations and those of your Affiliates and
Representatives under Section 11 of the Cooperation Agreement. 

  

	 	3.	 Notwithstanding anything to the contrary provided in this letter agreement, in the event you or any of your Affiliates or Representatives receive a
request or are required by deposition, interrogatory, request for documents, subpoena, civil investigative demand or similar process or pursuant to a formal request from a regulatory examiner (any such requested or required disclosure, an
“External Demand”) or otherwise pursuant to applicable law, regulation or the rules of any national securities exchange (as determined 

  
 2 

	 	
based on advice of outside legal counsel) to disclose all or any part of the Confidential Information, agree to, to the extent permitted by applicable law, (a) promptly notify the Company of
the existence, terms and circumstances surrounding such External Demand or other requirement, (b) consult with the Company on the advisability of taking legally available steps to resist or narrow such request or disclosure, and (c) in the
case of any External Demand, assist the Company, at the Company’s request and expense, in seeking a protective order or other appropriate remedy to the extent available under the circumstances. In the event that such protective order or other
remedy is not obtained or not available or that the Company waives compliance with the provisions hereof, (i) you or your Affiliates or Representatives, as the case may be, may disclose only that portion of the Confidential Information which
you or your Affiliates or Representatives are advised by counsel is legally required to be disclosed and to the extent you or your Affiliates or Representatives are advised by counsel is legally required, and, in the case of any External Demand, you
or your Affiliates or Representatives shall, at the Company’s request and expense, exercise reasonable efforts to obtain assurance that confidential treatment will be accorded such Confidential Information, and (ii) you or your Affiliates
or Representatives shall not be liable for such disclosure, unless such disclosure was caused by or resulted from a previous disclosure by you or your Affiliates or Representatives in violation of this letter agreement. Notwithstanding the
foregoing, except in the case of an External Demand, you and your Affiliates and Representatives may disclose Confidential Information pursuant to this paragraph 3 if but only if such disclosure requirement does not arise from a breach of paragraph
9 of the Cooperation Agreement. For the avoidance of doubt, it is understood and agreed that there shall be no “applicable law”, “regulation” or “rule” requiring you or your Affiliates or Representatives to disclose any
Confidential Information solely by virtue of the fact that, absent such disclosure, you or your Affiliates or Representatives would be prohibited from purchasing, selling or engaging in derivative or other voluntary transactions with respect to the
securities of the Company or you or your Affiliates or Representatives would be unable to file any proxy materials in compliance with Section 14(a) of the Exchange Act or the rules promulgated thereunder. 

 

	 	4.	Upon the Company’s demand, you shall either promptly (at your option) (a) destroy the Confidential Information and any copies thereof, or (b) return to the Company all Confidential Information and any
copies thereof, and, in either case, confirm in writing to the Company that all such material has been destroyed or returned, as applicable, in compliance with this letter agreement, provided that (i) you and your Affiliates and Representatives
shall be permitted to retain Confidential Information to the extent necessary to comply with applicable law or such person’s document retention policies designed to ensure compliance with applicable law and (ii) the foregoing shall not
require the deletion of Confidential Information from computer archives maintained in the ordinary course (provided that you and your Affiliates and Representatives shall continue to be bound by the obligations of confidentiality hereunder with
respect to such Confidential Information for such period of time as you and such Affiliates or Representatives retain such Confidential Information). 

  

	 	5.	 You acknowledge and agree that money damages would not be a sufficient remedy for any breach (or threatened breach) of this letter agreement by you or
your Affiliates or 

  
 3 

	 	
Representatives and that the Company shall be entitled to equitable relief, including injunction and specific performance, as a remedy for any such breach (or threatened breach), without proof of
damages, and each party further agrees to waive, and use its reasonable best efforts to cause its Affiliates to waive any requirement for the securing or posting of any bond in connection with any such remedy. Such remedies shall not be the
exclusive remedies for a breach of this letter agreement, but will be in addition to all other remedies available at law or in equity. 

  

	 	6.	You agree that (a) none of the Company or their respective Affiliates or representatives shall have any liability to you or any of your Affiliates or Representatives resulting from the selection, use or content of
the Confidential Information by you or your Affiliates or Representatives and (b) none of the Company or their respective Affiliates or representatives makes any representation or warranty, express or implied, as to the accuracy or completeness
of any Confidential Information. This letter agreement shall not create any obligation on the part of the Company or any of its subsidiaries, Affiliates or representatives to provide you or your Affiliates or Representatives with any Confidential
Information, nor shall it entitle you or your Affiliates or Representatives (other than the Investor Designee in his capacity as a director of the Company) to participate in any Board or committee meetings. All Confidential Information shall remain
the property of the Company and its subsidiaries. Neither you nor any of your Affiliates or Representatives shall by virtue of any disclosure of and/or your or their use of any Confidential Information acquire any rights with respect thereto, all of
which rights shall remain exclusively with the Company and its subsidiaries. 

  

	 	7.	No failure or delay by any party or any of its representatives in exercising any right, power or privilege under this letter agreement shall operate as a waiver thereof, and no modification hereof shall be effective,
unless in writing and signed by the parties. 

  

	 	8.	The illegality, invalidity or unenforceability of any provision hereof under the laws of any jurisdiction shall not affect its legality, validity or enforceability under the laws of any other jurisdiction, nor the
legality, validity or enforceability of any other provision. 

  

	 	9.	This letter agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware. The parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the Chancery
Courts in the State of Delaware and the United States District Court for the District of the State of Delaware for any action, suit or proceeding arising out of or relating to this letter agreement, and agree not to commence any action, suit or
proceeding related thereto except in such courts. 

  

	 	10.	This letter agreement and the Cooperation Agreement (including the exhibits thereto) contain the entire understanding of the parties with respect to the subject matter hereof and thereof and supersedes all prior or
contemporaneous agreements or understandings, whether written or oral. This letter agreement may be amended only by an agreement in writing executed by the parties hereto. 

 

	 	11.	 This letter agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which shall constitute the
same agreement. One or more counterparts of this letter agreement may be delivered by telecopier or pdf electronic 

  
 4 

	 	
transmission, with the intention that they shall have the same effect as an original counterpart hereof. 

  

	 	12.	Except as otherwise set forth herein, this letter agreement shall terminate three (3) years from the date on which the Investor Designee ceases to be a director of the Company; provided that you and your Affiliates
shall maintain in accordance with the confidentiality obligations set forth herein any Confidential Information constituting trade secrets for such longer time as such information constitutes a trade secret of the Company or any of its subsidiaries
under applicable law; and provided further that any liability for breach of this letter agreement prior to such termination shall survive such termination. 

[Remainder of the page intentionally left blank] 

  
 5 

			
	Very truly yours,
	
	CITRIX SYSTEMS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	Confirmed and Agreed to:
	
	ELLIOTT ASSOCIATES, L.P.
	 By: Elliott Capital Advisors, L.P.,

its General Partner

	 By: Braxton Associates, Inc.,
 its
General Partner

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	ELLIOTT INTERNATIONAL, L.P.
	 By: Elliott International Capital Advisors Inc.,

as Attorney-in-Fact

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	ELLIOTT INTERNATIONAL CAPITAL ADVISORS INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

  
 6Exhibit 10.3

 

DEMAND
PROMISSORY NOTE

 

	$20,000.00	February 1, 2015

 

FOR VALUE RECEIVED,
Focus Universal Inc., a Nevada corporation (the “Maker”), does hereby promise to pay to Perfecular Inc. or their
assignee (the “Holder”) on demand, the principal sum of twenty thousand dollars ($20,000.00) (the “Principal”)
together with interest as set forth herein (the “Interest”), in lawful currency of the United States.

 

1.  Interest
Rate.

 

(a)The Interest payable
by the Maker hereunder shall accrue at the lowest applicable federal rate per annum (the “Interest”).

 

2.  Payment.

 

(a)All Principal
and Interest payable hereunder shall be payable to the Holder at such place or places as the Holder may direct from time to time,
in such coin and currency as shall be legal tender at the time of payment for the payment of public and private debts in the United
States of America.

 

(b)All Principal
and Interest payable by the Maker hereunder shall be payable upon Holder’s demand (the “Due Date”).
This Note may be repaid prior to the Due Date without premium or penalty, in whole or in part at any time.

 

3.  Collection
Expense. If there is an Event of Default, as defined below, under this Promissory Note and this Promissory Note is placed
in the hands of an attorney for collection, or in the event that this Promissory Note is collected in whole or in part by suit
or through probate or bankruptcy proceedings, or other legal proceedings of any kind (an “Event of Default”),
the Maker agrees to pay, in addition to all the sums payable hereunder, the Holder’s reasonable expenses of collection, including
without limitation, reasonable attorneys’ fees and disbursements, whether or not suit is brought and through all appeals.

 

4.  General
Provisions. Time shall be of the essence with respect to the terms of this Promissory Note. This Promissory Note cannot
be changed or modified orally.

 

5.  Assignment.
The Holder shall have the right to assign its rights hereunder as determined by the Holder in its sole discretion and without the
consent of the Maker. The Maker shall not have the right to assign its obligations hereunder without the consent of the Holder.

 

6.  Governing
Law. This Promissory Note shall be construed in accordance with and governed by the laws of Nevada.

 

    	1

    	 

    

 

THIS PROMISSORY NOTE is executed
and made effective as of the date written above.

 

 

	 	MAKER:
	 	 
	 	Focus Universal Inc.
	 	 	 
	 	By:	/s/ Desheng Wang
	 	 	Desheng Wang
	 	Its:	CEO

 

 

 

 

 

 

    	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]